American Society of Hematology

SHERPA: Blue

People

  1. Giralt
    Giralt
  2. Zelenetz
    Zelenetz
  3. Levine
    Levine
  4. Perales
    Perales
  5. Tallman
    Tallman
  6. O'Reilly
    O'Reilly
  7. Horwitz
    Horwitz
  8. Devlin
    Devlin
  9. Palomba
    Palomba
  10. Abdel-Wahab
    Abdel-Wahab

Groups

  1. Department of Medicine (4000)
  2. Hematologic Malignancies, Division of (3803)
  3. Center for Hematologic Malignancies (3680)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1343)
  6. Sloan Kettering Institute Faculty (1075)
  7. Bone Marrow Transplant (988)
  8. Center for Molecular Imaging and Biotechnology (CMIB) (955)
  9. Lymphoma (941)
  10. Tow Center for Developmental Oncology (TCDO) (882)
Search Within
Formats
  1. Meeting Abstract (4150)
  2. Journal Article (1257)
  3. Research Letter (46)
  4. Review (44)
  5. Editorial (35)
  6. Guidelines (13)
  7. Correspondence (7)
  8. Miscellaneous (3)
Groups
  1. Department of Medicine (4000)
  2. Hematologic Malignancies, Division of (3803)
  3. Center for Hematologic Malignancies (3680)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1343)
  6. Sloan Kettering Institute Faculty (1075)

More Groups

People
  1. Sergio Giralt (348)
  2. Andrew Zelenetz (341)
  3. Ross Levine (316)
  4. Miguel-Angel Perales (312)
  5. Martin Tallman (301)
  6. Richard O'Reilly (281)

More People

Years
  1. 2025 (64)
  2. 2024 (428)
  3. 2023 (478)
  4. 2022 (369)
  5. 2021 (284)
  6. 2020 (261)

More Years

Publications
  1. Blood (5174)
  2. Blood Advances (331)
  3. Hematology-American Society of Hematology Education Program (50)

Results (5555)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Real-world treatment of pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia using tisagenlecleucel that is out of specification for commercial release
    Meeting Abstract

    Rossoff, J.; Baggott, C.; Prabhu, S.; Pacenta, H.; Phillips, C. L.; Stefanski, H.; Talano, J. A.; Moskop, A.; Margossian, S. P.; Verneris, M. R.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Multi-center phase II study of oral azacitidine (CC-486) plus CHOP as initial treatment for peripheral T-cell lymphoma (PTCL)
    Meeting Abstract

    Ruan, J.; Moskowitz, A. J.; Mehta-Shah, N.; Sokol, L.; Chen, Z.; Rahim, R.; Song, W.; Van Besien, K.; Horwitz, S. M.; Rutherford, S. C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Local review versus (vs) central review of fluorodeoxyglucose positron emission tomography (FDG-PET) in diffuse large B-cell lymphoma (DLBCL): Results from the CALGB 50303 trial [alliance]
    Meeting Abstract

    Ruppert, A. S.; Pederson, L. D.; Knopp, M. V.; Poon, D.; Zhang, J.; Kahl, B. S.; Friedberg, J. W.; Schwartz, L. H.; Wilson, W. H.; Leonard, J. P.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Atypical peripheral blood cell morphology in COVID-19 (Sars-CoV-2) patients from Mount Sinai health system in New York City
    Meeting Abstract

    Salib, C.; Khattar, P.; Cheng, J.; Teruya-Feldstein, J.
    Blood (2020)

    Fulltext@MSK | Save
  • HORIZON (OP-106): Melflufen plus dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) exposed to prior alkylator therapy-subgroup analysis
    Meeting Abstract

    Rodríguez-Otero, P.; Mateos, M. V.; Oriol, A.; Larocca, A.; Creixenti, J. B.; Cavo, M.; Leleu, X.; Norkin, M.; Nadeem, O.; Hiemenz, J. W.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Worldwide examination of patients with CLL hospitalized for COVID-19
    Meeting Abstract

    Roeker, L. E.; Scarfo, L.; Chatzikonstantinou, T.; Abrisqueta, P.; Eyre, T. A.; Cordoba, R.; Prat, A. M.; Villacampa, G.; Leslie, L. A.; Koropsak, M.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • HORIZON (OP-106): Melflufen plus dexamethasone (dex) in 55 patients (pts) with relapsed/refractory multiple myeloma (RRMM) with extramedullary disease (EMD)-subgroup analysis
    Meeting Abstract

    Richardson, P. G.; Mateos, M. V.; Oriol, A.; Larocca, A.; Cavo, M.; Rodriguez-Otero, P.; Leleu, X.; Norkin, M.; Nadeem, O.; Hiemenz, J. W.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Favorable outcomes among patients with T-cell/histiocyte-rich large B-cell lymphoma treated with higher-intensity therapy in the rituximab era
    Meeting Abstract

    Robin, E. T.; Drill, E.; Batlevi, C. L.; Caron, P.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Intlekofer, A. M.; Joffe, E.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Secondary graft-versus-host disease (GVHD) prophylaxis with oral proteasome inhibitor ixazomib is associated with low incidence of recurrent, late acute and chronic GVHD and facilitated calcineurin inhibitor taper within the first year post allogeneic stem cell transplantation
    Meeting Abstract

    Rodriguez, N.; Lee, J.; Flynn, L.; Murray, F.; Devlin, S.; Izquierdo, C. S.; Cho, C.; Dahi, P. B.; Giralt, S. A.; Sauter, C. S.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Analysis of the global methylation profile of accelerated and blast phase myeloproliferative neoplasms and its association with response to decitabine-based therapy
    Meeting Abstract

    Rampal, R. K.; Yang, Q.; Koche, R. P.; McGovern, E.; Famulare, C.; Weinberg, R. S.; Mascarenhas, J.; Levine, R. L.; Hoffman, R.; Figueroa, M. E.
    Blood (2020)

    Fulltext@MSK | Save